Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May 1;4(5):580-581.
doi: 10.34067/KID.0000000000000136. Epub 2023 May 25.

Targeting Fibrosis Pathways in Alport Syndrome-Is it Too Late?

Michelle N Rheault  1
Affiliations
Editorial

Targeting Fibrosis Pathways in Alport Syndrome-Is it Too Late?

Michelle N Rheault. Kidney360. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

M.N. Rheault reports the following—consultancy: Otsuka; ownership interest: Microsoft and Protolabs; research funding: Chinook, Kaneka, Reata, River 3 Renal, Sanofi, and Travere; patents or royalties: Wolters Kluwer-Royalties for Textbook of Glomerulonephritis as editor; and advisory or leadership role: Alport Syndrome Foundation Medical Advisory Board, NephJC (501c3) Board of Directors, Peds Nephrology Research Consortium (501c3) Steering Committee, and Women In Nephrology (501c3), all unpaid.

Comment on

References

    1. Kashtan CE, Gross O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol. 2021;36(3):711–719. doi:10.1007/s00467-020-04819-6 - DOI - PubMed
    1. Omachi K, O’Carroll C, Miner JH. PPARδ agonism ameliorates renal fibrosis in an Alport syndrome mouse model. Kidney360. 2023;4(3):341–348. doi:10.34067/KID.0006662022 - DOI - PMC - PubMed
    1. Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol. 2021;18(12):809–823. doi:10.1038/s41569-021-00569-6 - DOI - PubMed
    1. Omachi K Kaseda S Yokota T, et al. . Metformin ameliorates the severity of experimental Alport syndrome. Sci Rep. 2021;11(1):7053. doi:10.1038/s41598-021-86109-1 - DOI - PMC - PubMed
    1. Gomez IG MacKenna DA Johnson BG, et al. . Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest. 2015;125(1):141–156. doi:10.1172/JCI75852 - DOI - PMC - PubMed